Germany Pharmaceuticals and Healthcare Report Q3 2014

  • May 2014
  • -
  • Business Monitor International
  • -
  • 134 pages

Includes 3 FREE quarterly updates
BMI View: Germany's medicines pricing regime will continue to restrict drugmakers' revenue streams. The AMNOG has proved to be tough, with the majority of medicine reimbursement prices lying under the average of or below the lowest of the European reference country basket. Additionally, legislators have voted to continue the 2010 implemented price freeze on reimbursed drugs until the end of 2017. However, the long term and clear nature of the measures implemented by the government is a much more structured medicine pricing regime than the numerous emergency measures implemented by south European governments - which are highly disruptive to drugmakers' strategies and revenue streams.

Headline Expenditure Projections
- Pharmaceuticals: EUR40.02bn (USD52.82bn) in 2013 to EU39.95bn (USD52.33bn) in 2014; -0.2% in local currency terms and -0.9% in US dollar terms.
- Healthcare: EUR293.95bn (USD388.02bn) in 2013 to EUR300.54bn (USD393.71bn) in 2014; +2.2% in local currency terms and 1.5% in US dollar terms.

Table Of Contents

Germany Pharmaceuticals and Healthcare Report Q3 2014
BMI Industry View . 7
SWOT .. 9
Political 11
Economic ... 12
Business Environment . 13
Industry Forecast 14
Pharmaceutical Market Forecast .. 14
Table: Pharmaceutical Sales, Historical Data And Forecasts (Germany 2010-2018) 15
Healthcare Market Forecast ... 16
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Germany 2010-2018) . . 17
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Germany 2010-2018) 17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Germany 2010-2018) . . 18
Prescription Drug Market Forecast ... 19
Table: Retail Pharmaceutical Expenditure, 2003-2010 (EURbn) . . 20
Table: Retail Pharmaceutical Expenditure, 2003-2010 (Packages, ms) . . . 20
Table: Retail Pharmaceutical Expenditure, 2003-2010 (Average Price per Pack, EUR) . . 20
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Germany 2010-2018) 21
Patented Drug Market Forecast ... 22
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Germany 2010-2018) 23
Generic Drug Market Forecast .... 24
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Germany 2010-2018) . 25
OTC Medicine Market Forecast ... 26
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Germany 2010-2018) . . 27
Pharmaceutical Trade Forecast ... 28
Table: Pharmaceutical Trade Data And Forecasts USDmn (Germany 2012-2018) . . . 29
Table: Pharmaceutical Trade Data And Forecasts, EURmn (Germany 2012-2018) . . 29
Other Healthcare Data 30
Key Risks To BMI's Forecast Scenario .... 31
Macroeconomic Forecasts 32
Table: Germany - Economic Activity . . . 37
Industry Risk Reward Ratings 38
Western Europe Risk/Reward Ratings . 38
Germany Risk/Reward Ratings 43
Rewards ... 43
Risks ... 43
Market Overview . 44
Industry Trends And Developments 45
Epidemiology . 45
Healthcare Sector 46
Health Insurance . 46
Healthcare Sector Reforms ... 47
Research and Development 49
Biotechnology Sector . 53
Table: Biotechnology Sector, 2008-09 . . 53
Clinical Trials 55
Regulatory Development ... 56
Table: BfArM Drug Registration Activity, 2006-10 56
Intellectual Property Regime . 58
Pricing Regime .... 60
Table: Price Build-Up In The German Pharmaceutical Market . . . 61
Table: Selected AMNOG Drug Assessments 63
Reimbursement Regime ... 66
Table: Top 10 GKV Selling Drug Brands, 2009-2010 (EURmn) . . . 67
Parallel Imports ... 70
Competitive Landscape 71
Table: Pharmaceutical Production, 1990-2010 71
Table: Leading German Pharmaceutical Companies . . 73
Wholesale Sector . 75
Table: Members of the Association of Pharmaceutical Wholesalers (PHAGRO), 2012 . . . 75
Retail Sector .. 78
Company Profile .. 84
Bayer HealthCare .. 84
Boehringer Ingelheim .. 91
STADA Arzneimittel .... 98
Grünenthal .... 104
Merck KGaA . 107
GlaxoSmithKline (GSK) .. 113
Pfizer . 116
Sanofi . 119
Merck and Co ... 122
Demographic Forecast .... 124
Table: Germany's Population By Age Group, 1990-2020 ('000) . . 125
Table: Germany's Population By Age Group, 1990-2020 (% of total) 126
Table: Germany's Key Population Ratios, 1990-2020 127
Table: Germany's Rural And Urban Population, 1990-2020 . 127
Glossary ... 128
Methodology . 130
Pharmaceutical Expenditure Forecast Model .. 130
Healthcare Expenditure Forecast Model .... 130
Notes On Methodology .. 131
Risk/Reward Ratings Methodology . 132
Ratings Overview .... 133
Table: Pharmaceutical Risk/Reward Ratings Indicators . . 133
Indicator Weightings .... 134

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • November 2014
  • by Global Data

PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2023 Summary Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the ...

PharmaPoint: Irritable Bowel Syndrome - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Irritable Bowel Syndrome - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • December 2014
  • by Global Data

PharmaPoint: Irritable Bowel Syndrome - Global Drug Forecast and Market Analysis to 2023 Summary Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with ...

OpportunityAnalyzer: Celiac Disease - Opportunity Analysis and Forecast to 2023

OpportunityAnalyzer: Celiac Disease - Opportunity Analysis and Forecast to 2023

  • $ 7 995
  • Industry report
  • November 2014
  • by Global Data

OpportunityAnalyzer: Celiac Disease - Opportunity Analysis and Forecast to 2023 Summary There are no pharmacological treatments that are indicated for celiac disease and the current standard of care treatment ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.